Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI China ETF (MCHI) vs Novartis AG (NVS) Price & Performance

iShares MSCI China ETFTrade
Novartis AGTrade

Price performance (Past 24H)

Key statistics

iShares MSCI China ETF vs Novartis AG — how do they compare? iShares MSCI China ETF trades at $55.62, while Novartis AG trades at $154.71 (market cap $298.18B). The key difference: Novartis AG pays a 3.02% dividend while iShares MSCI China ETF pays none, and Novartis AG is trading nearer its 52-week high, iShares MSCI China ETF nearer its low. Which is the better fit depends on your goals.

MCHINVS
Sector
Broad Market / FactorHealth
52-Week High
$66.99$168.62
52-Week Low
$50.48$119.31
Market Cap
$298.18B
Enterprise Value
$339.50B
Dividend Yield
3.02%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI China ETF

MCHI trades at $56.57, up 1.19% with strong technical momentum showing bullish moving averages and institutional buying interest. The ETF benefits from China's export strength and AI-driven manufacturing growth, though key financial ratios remain undisclosed. Recent news highlights China's 23% July export surge and $295 billion AI infrastructure plan, creating positive sentiment around Chinese equities.

Outlook remains cautiously optimistic with technical indicators signaling strength but RSI levels suggesting potential overbought conditions. Key risks include US-China trade tensions and regulatory uncertainties, while institutional flows and China's tech investment push provide upside catalysts for continued momentum.

Novartis AG

Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.

The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares MSCI China ETF

MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.

Read more on MCHI

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS